Also, TAMs are key players in the antitumor activity of selected monoclonal antibodies (mAbs) such as rituximab (anti-CD20), trastuzumab (anti-HER2), cetuximab (anti-EGFR), and daratumumab (anti-CD38), as they express FcγR to perform tumor-cell killing and phagocytosis (127, 160). The gene discussed is EGFR; the disease is neoplasm.